Avid Bioservices Inc (CDMO)

[sulaco]

Paul, true, Bavi is sitting smack dab in the middle of emerging


immuno-oncology agents. Which is FANTASTIC.


As an aside, those who are critical of King's performance in the CS webcast 11/12/2013 are officially NUTS.

King's performance was down-to-earth, direct, and organized. You could sense his optimism and confidence. The general sense from him was,

"Hey, a lot of this is settled science. We KNOW Bavi decreases MDSCs and gets macrophages and dendritic cells going again. We know it supports the production of immunostimulatory cytokines. This is accepted science. We know how to pair Bavi up with the right agents now. It does well with docetaxel and paclitaxel. It does well with radiation. It does well with ANYTHING that is immunostimulatory. We won't pair it up with anything from here on out that is immunosuppressant. We know we need the type of patients that will live long enough to see the separation of the KM curves that is so indicative of immunotherapeutic agents."

My take is this is why Pancreatic data didn't pan out well. The population didn't have a good baseline immune system. They didn't live long enough to give Bavi time to work and to see the KM curves extend.

In my view, good progress lies ahead for the cancer patient, the company, and shareholders.

GLTAL!

Best,

Joe